Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X–Linked Hypophosphatemia in Children

Feb 27, 2018

Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa Kirin International PLC (Kyowa Kirin International) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE: Ultragenyx) today announce that Crysvita (burosumab) has received a positive European Commission decision granting a conditional marketing authorisation to Kyowa ...

Read More

Researchers in Japan develop a novel biosensing method

Feb 21, 2018

The group has developed a nonlinear optical crystal (NLOC) chip, which combines terahertz (THz) waves with a microfluidic device. A group of researchers from Osaka University, Japan has developed a sensing method with the potential to significantly contribute to early ...

Read More